ART1 and neoplasm: The recent discovery of how tumour-expressed ART1 allows tumours to co-opt the immune homeostatic mechanism of NICD suggests that targeted ART1-inhibition would counter this immune escape mechanism and maintain the viability of critical anti-tumour immune cells (55).